Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity

Toxicology

Volumn 216, Issue 2-3, 2005, Pages 106-121

  Szebeni, Janos ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Allergy; Anaphylactoid reaction; Anaphylatoxins; Cancer chemotherapy; Cremophor EL; Micelles; Radiocontrast agents; Taxol

Indexed keywords

AMPHOPHILE; AMPHOTERICIN B LIPID COMPLEX; ANAPHYLATOXIN; COMPLEMENT COMPONENT C5A; CONTRAST MEDIUM; CREMOPHOR; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; IMMUNOGLOBULIN E; LIPOSOME; NANOPARTICLE; PACLITAXEL; POLYMER;

ALLERGY; ANAPHYLAXIS; BASOPHIL; CARDIOVASCULAR DISEASE; COMPLEMENT SYSTEM; DRUG DELIVERY SYSTEM; HYPERSENSITIVITY REACTION; IMMUNOTOXICITY; MAST CELL; MEDICAL TECHNOLOGY; NONHUMAN; PATHOLOGY; PREDICTION; PREVALENCE; PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SLOW RELEASE FORMULATION; SWINE;

ANAPHYLAXIS; ANIMALS; COMPLEMENT PATHWAY, CLASSICAL; DISEASE MODELS, ANIMAL; HUMANS; LIPOSOMES; NANOSTRUCTURES;

SUS SCROFA;

EID: 28244466864     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2005.07.023     Document Type: Review

References (122)

1. J.M. Aguado, M. Hidalgo, I. Moya, J.M. Alcazar, M.J. Jimenez, and A.R. Noriega Ventricular arrhythmias with conventional and liposomal amphotericin Lancet 342 8881 1993 1239
2. D.S. Alberts, and D.J. Garcia Safety aspects of pegylated liposomal doxorubicin in patients with cancer Drugs 54 Suppl. 4 1997 30 45
3. C.R. Alving, S.C. Kinsky, J.A. Haxby, and C.B. Kinsky Antibody binding and complement fixation by a liposomal model membrane Biochemistry 8 1969 1582 1587
4. J.K. Aronson, and R.E. Ferner Joining the DoTS: new approach to classifying adverse drug reactions Br. Med. J. 327 2003 1222 1225
5. A.E. Athanassiou, D. Bafaloukos, D. Pectasidis, and M. Dimitriadis Acute vasomotor response - a reaction to etoposide J. Clin. Oncol. 6 1988 1204 1205
6. G. Barratt Colloidal drug carriers: achievements and perspectives Cell. Mol. Life Sci. 60 2003 21 37
7. B.J. Barrett, P.S. Parfrey, H.M. Vavasour, F. O'Dea, G. Kent, and E. Stone A comparison of nonionic, low-osmolality radiocontrast agents with ionic, high-osmolality agents during cardiac catheterization Med. J. Aust. 154 1991 766 772
8. R.H. Blum, M.B. Garnick, M. Israel, G.P. Canellos, I.C. Henderson, and E. Frei III Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog Cancer Treat. Rep. 63 1979 919 928
9. M. Bodo, J. Szebeni, J. Baranyi, S. Savay, F.J. Pearce, C.R. Alving, and R. Bünger Cerebrovascular involvement in liposome-induced cardiopulmonary distress in pigs J. Liposome Res. 15 2005 3 14
10. M.A. Bookman, D.D. Kloth, P. Kover, S. Smolinski, and R.F. Ozols Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions Ann. Oncol. 8 1997 611 614
11. M.A. Bookman, D.D. Kloth, P.E. Kover, S. Smolinski, and R.F. Ozols Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions Semin. Oncol. 24 Suppl. 19 1997 S1913 S1915
12. R. Boumiza, G. Monneret, M.F. Forissier, J. Savoye, M.C. Gutowski, W.S. Powell, and J. Bienvenu Marked improvement of the basophil activation test by detecting CD203c instead of CD63 Clin. Exp. Allergy 33 2003 259 265
13. A.H. Brouwers, D.J. De Jong, E.T. Dams, W.J. Oyen, O.C. Boerman, P. Laverman, T.H. Naber, G. Storm, and F.H. Corstens Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease J. Drug Target 8 2000 225 233
14. S. Cabriales, J. Bresnahan, D. Testa, B.M. Espina, D.T. Scadden, M. Ross, and P.S. Gill Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases Oncol. Nurs. Forum 25 1998 67 70
15. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving, and F.M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437
16. A.K. Cheung, C.J. Parker, and M. Hohnholt Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro Kidney Int. 46 1994 1680 1687
17. A. Chonn, P.R. Cullis, and D.V. Devine The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes J. Immunol. 146 1991 4234 4241
18. R.R.A. Coombs, and P.G.H. Gell Classification of allergic reactions responsible for drug hypersensitivity reactions R.R.A. Coombs P.G.H. Gell Clinical Aspects of Immunology second ed. 1968 Davis Philadelphia, PA 575 596
19. A. Coune, J.P. Sculier, J. Frühling, P. Stryckmans, C. Brassine, G. Ghanem, C. Laduron, G. Atassi, J.M. Ruysschaert, and J. Hildebrand Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man Cancer Treat. Rep. 67 1983 1031 1033
20. E.T. Dams, W.J. Oyen, O.C. Boerman, G. Storm, P. Laverman, P.J. Kok, W.C. Buijs, H. Bakker, J.W. van der Meer, and F.H. Corstens 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation J. Nucl. Med. 41 2000 622 630
21. S. de Marie Liposomal and lipid-based formulations of amphotericin B Leukemia 10 Suppl. 2 1996 S93 S96
22. P. Demoly, B. Lebel, D. Messaad, H. Sahla, M. Rongier, J.P. Daures, P. Godard, and J. Bousquet Predictive capacity of histamine release for the diagnosis of drug allergy Allergy 54 1999 500 506
23. J. Descotes, and G. Choquet-Kastylevsky Gell and Coombs's classification: is it still valid? Toxicology 158 2001 43 49
24. ® (Doxorubicin HCl liposome injection) in Refractory AIDS-related Kaposi's Sarcoma. Doxil Clinical Series vol. 1 1996 Gardiner-Caldwell SynerMed Califon, NJ pp. 1-8
25. J.R. Eckardt, E. Campbell, H.A. Burris, G.R. Weiss, G.I. Rodriguez, S.M. Fields, A.M. Thurman, N.W. Peacock, P. Cobb, and M.L. Rothenberg A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon Am. J. Clin. Oncol. 17 1994 498 501
26. D.M. Essayan, A. Kagey-Sobotka, P.J. Colarusso, L.M. Lichtenstein, R.F. Ozols, and E.D. King Successful parenteral desensitization to paclitaxel J. Allerg. Clin. Immunol. 97 1996 42 46
27. R. Fattori, R. Piva, F. Schicchi, A. Pancrazi, G. Gabrielli, A. Marzocchi, G. Piovaccari, A. Blandini, and B. Magnani Iomeprol and iopamidol in cardiac angiography: a randomised, double-blind parallel-group comparison N. Engl. J. Med. 326 1992 431 436
28. S.D. Fossa, N. Aass, and G. Paro A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma Eur. J. Cancer 34 1998 1131 1132
29. A. Gabizon, and F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 1997 15 21
30. A.A. Gabizon, and F.M. Muggia Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors M.C. Woodle G. Storm Long-Circulating Liposomes: Old Drugs, New Therapeutics 1998 Landes Bioscience Austin, TX 155 174
31. K. Garber Improved Paclitaxel formulation hints at new chemotherapy approach J. Natl. Cancer Inst. 96 2004 90 91
32. A. Genovese, C. Stellato, V. Patella, B. Lamparter-Schummert, G. de Crescenzo, M. Adt, and G. Marone Contrast media are incomplete secretagogues acting on human basophils and mast cells isolated from heart and lung, but not skin tissue Eur. J. Radiol. 18 Suppl. 1 1994 S61 S66
33. P.S. Gill, B.M. Espina, F. Muggia, S. Cabriales, A. Tulpule, J.A. Esplin, H.A. Liebman, E. Forssen, M.E. Ross, and A.M. Levine Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin J. Clin. Oncol. 13 1995 996 1003
34. P.S. Gill, J. Wernz, D.T. Scadden, P. Cohen, G.M. Mukwaya, J.H. von Roenn, M. Jacobs, S. Kempin, I. Silverberg, G. Gonzales, M.U. Rarick, A.M. Myers, F. Shepherd, C. Sawka, M.C. Pike, and M.E. Ross Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J. Clin. Oncol. 14 1996 2353 2364
35. P.M. Girard, O. Bouchaud, A. Goetschel, G. Mukwaya, G. Eestermans, M. Ross, W. Rozenbaum, and A.G. Saimot Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma AIDS 10 1996 753 757
36. R.G. Grainger Intravascular radiologic iodinated contrast media R.G. Grainger D.J. Allison Diagnostic Radiology: A Textbook of Medical Imaging 2001 Churchill Livingstone Oxford, UK 27 41
37. P.A. Greenberger Contrast media reactions J. Allergy Clin. Immunol. 74 1984 600 605
38. E. Grosen, E. Siitari, E. Larrison, C. Tiggelaar, and E. Roecker Paclitaxel hypersensitivity reactions related to bee-sting allergy Lancet 355 2000 288 289
39. P. Guaglianone, K. Chan, E. DelaFlor-Weiss, R. Hanisch, S. Jeffers, D. Sharma, and F. Muggia Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome) Invest. New Drugs 12 1994 103 110
40. H.J. Guchelaar, C.H. ten Napel, E.G. de Vries, and N.H. Mulder Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review Clin. Oncol. 6 1994 40 48
41. K.L. Hastings Implications of the new FDA/CDER immunotoxicology guidance for drugs Int. Immunopharmacol. 11 2002 1613 1618
42. J.A. Haxby, C.B. Kinsky, and S.C. Kinsky Immune response of a liposomal model membrane Proc. Natl. Acad. Sci. U.S.A. 61 1968 300 307
43. D.A. Henry, D.B. Evans, and J. Robertson The safety and cost-effectiveness of low osmolar contrast media. Can economic analysis determine the real worth of a new technology? Drug Saf. 1991 28 36
44. S.J. Hong, J.T. Wong, and K.J. Bloch Reactions to radiocontrast media Allergy Asthma Proc. 23 2002 347 351
45. A.C. Hunter, and S.M. Moghimi Synthetic polymers in 21st century therapeutics: the way forward Drug Discov. Today 8 2003 154 156
46. R.L. Hunter, and B. Bennett The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers J. Immunol. 133 1984 3167 3175
47. R.L. Hunter, and B. Bennett Modulation of antigen presentation and host mediators by block copolymer adjuvants Prog. Leuk. Biol. 6 1987 181 190
48. R.L. Hunter, J. McNicholl, and A.A. Lal Mechanisms of action of nonionic block copolymer adjuvants AIDS Res. Hum. Retroviruses 10 Suppl. 2 1994 S95 S98
49. H. Katayama, A. Spinazzi, X. Fouillet, M. Kirchin, P. Taroni, and A. Davies Iomeprol: current and future profile of a radiocontrast agent Invest. Radiol. 36 2001 87 96
50. D. Kessel Properties of cremophor EL micelles probed by fluorescence Photochem. Photobiol. 56 1992 447 451
51. D. Kessel, K. Woodburn, D. Kecker, and E. Sykes Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal Oncol. Res. 7 1995 207 212
52. W.P. Kolb, J.H. Lang, and E.C. Lasser Nonimmunologic complement activation in normal human serum induced by radiographic contrast media J. Immunol. 1978 1232 1238
53. M.G. Kris, J.P. O'Connell, and R.J. Gralla A phase I trial of Taxol given as 3-hour infusions every 21 days Cancer Treat. Rep. 70 1986 605 607
54. S. Kumar, and R. Mahalingam Anaphylactoid reactions to radiocontrast agents Pediatr. Rev. 22 2001 356
55. G.S. Kwon Polymeric micelles for delivery of poorly water-soluble compounds Crit. Rev. Ther. Drug. Carrier Syst. 20 2003 357 403
56. R.B.S. Laing, L.J.R. Milne, C.L.S. Leen, G.P. Malcolm, and A.J.W. Steers Anaphylactic reactions to liposomal amphotericin Lancet 344 1994 682
57. J.H. Lang, E.C. Lasser, and W.P. Kolb Activation of serum complement by contrast media Invest. Radiol. 1976 303 308
58. E.C. Lasser, J.H.A. Lang, S.G. Lyon, and A.E. Hamblin Changes in complement and coagulation factors in a patient suffering a severe anaphylactoid reaction to injected contrast material: some considerations of pathogenesis Invest. Radiol. 15 1980 S6 S12
59. E.C. Lasser, M. Sovak, and J.H. Lang Development of contrast media idiosyncrasy in the dog J. Radiol. 119 1976 91 95
60. M. Lassus, D. Scott, and B. Leyland-Jones Allergic reactions associated with cremophor-containing antineoplastics (abstract) Proc. Annu. Meet. Am. Soc. Clin. Oncol. 4 1985 268
61. S.J. Levine, T.J. Walsh, A. Martinez, P.Q. Eichacker, G. Lopez-Berstein, and C. Natanson Cardiopulmonary toxicity after liposomal amphotericin B infusion Ann. Int. Med. 114 1991 664 666
62. P. Lieberman The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions Singapore Med. J. 30 1989 290 293
63. P. Lieberman Anaphylactoid reactions to radiocontrast materia Clin. Rev. Allergy 9 1991 319 338
64. K. Liszewski, and J.P. Atkinson The complement system W.E. Paul Fundamental Immunology third ed. 1993 Raven Press, Ltd. New York 917 939
65. W. Lorenz, H.J. Riemann, and A. Schmal Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent Agents Actions 7 1977 63 67
66. B.B. Lundberg A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol) J. Pharm. Pharmacol. 49 1997 16 21
67. ®)-induced complement activation in human sera; A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels Biochim. Biophys. Acta 1689 2004 103 113
68. T.E. Mollnes Therapeutic manipulation of thecomplement system J. Szebeni The Complement System: Novel Roles in Health and Disease 2004 Kluwer Boston 483 516
69. J.F. Money-Kyrle, F. Bates, J. Ready, B.G. Gazzard, R.H. Phillips, and F.C. Boag Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study Clin. Oncol. (R. Coll. Radiol.) 5 1993 367 371
70. V.R. Nannan Panday, M.T. Huizing, W.W. Ten Bokkel Huinink, J.B. Vermorken, and J.H. Beijnen Hypersensitvity reactions to the taxanes paclitaxel and docetaxel Clin. Drug Invest. 14 1997 418 427
71. K. Napolovlu The effect of epsilon-aminocaproic acid and prednisolone on the activation of the complement system due to X-ray contrast agents in rats in vitro Eksp. Klin. Farmakol. 1997 62 64
72. K. Napolovlu, E.N. Bolotova, and N.L. Shimanovskii The complement-activating action of modern X-ray contrast agents J. Eksp. Klin. Farmakol. 61 1998 60 64
73. M.M. Nerurkar, N.F.H. Ho, P.S. Burton, T.J. Vidmar, and R.T. Borchardt Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells J. Pharm. Sci. 86 1997 813 821
74. H. Nolte, H. Carstensen, and H. Hertz VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children Am. J. Ped. Hematol. Oncol. 10 1988 308 312
75. P.J. O'Dwyer, and R. Weiss Hypersensitivity reactions induced by etoposide Cancer Treat. Rep. 68 1984 959 961
76. R. Paradis, and M. Page New active paclitaxel amino acids derivatives with improved water solubility Anticancer Res. 18 1998 2711 2716
77. R.K. Ramanathan, V.V. Reddy, J.M. Holbert, and C.P. Belani Pulmonary infiltrates following administration of paclitaxel Chest 110 1996 289 292
78. D.S. Richardson, S.M. Kelsey, S.A. Johnson, M. Tighe, J.D. Cavenagh, and A.C. Newland Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma Invest. New Drugs 15 1997 247 253
79. O. Ringdén, E. Andström, M. Remberger, B.M. Svahn, and J. Tollemar Allergic reactions and other rare side effects of liposomal amphotericin Lancet 344 1994 1156 1157
80. E.K. Rowinsky Clinical pharmacology of Taxol Monogr. Natl. Cancer Inst. 15 1993 25 37
81. E.K. Rowinsky The development and utility of the taxane class of antimicrotubule chemotherapy agents Ann. Rev. Med. 48 1997 353 374
82. E.K. Rowinsky, and R.C. Donehower Paclitaxel (Taxol) N. Engl. J. Med. 332 1995 1004 1014
83. E.K. Rowinsky, W.P. McGuire, and T. Guarnieri Cardiac disturbances during the administration of Taxol J. Clin. Oncol. 9 1991 1704 1712
84. E.K. Rowinsky, N. Onetto, R.M. Canetta, E.A. Eisenhauer, and S.G. Arbuck Taxol: the first of the taxanes, an important new class of antitumor agents Semin. Oncol. 19 1992 646 662
85. E.K. Rowinsky, M. Wright, B. Monsarrat, and R.C. Donehower Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993 Ann. Oncol. 5 1994 S7 S16
86. P. Schneider, R.M. Klein, L. Dietze, D. Sohngen, M. Leschke, and A. Heyll Anaphylactic reaction to liposomal amphotericin (AmBisome) Br. J. Haematol. 102 1998 1108
87. C.D. Scripture, J. Szebeni, W.J. Loos, W.D. Figg, and A. Sparreboom Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of Taxol and Paxene Cancer Biol. Ther. 4 2005 555 560
88. N.R. Skroeder, S.H. Jacobson, L.E. Lins, and C.M. Kjellstrand Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis Artif. Organs 18 1994 880 887
89. N.R. Skroeder, P. Kjellstrand, B. Holmquist, C.M. Kjellstrand, and S.H. Jacobson Individual differences in biocompatibility responses to hemodialysis Int. J. Artif. Organs 17 1994 521 530
90. K.M. Skubitz, and A.P. Skubitz Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil) Anticancer Drugs 9 1998 45 50
91. P. Small, R. Satin, M.J. Palayew, and B. Hyams Prophylactic antihistamines in the management of radiographic contrast reactions Clin. Allergy 12 1982 289 294
92. C.A. Smith, C.V. Vogel, and H.J. Muller-Eberhard Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement J. Biol. Chem. 257 1982 9879 9882
93. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. Figg, M. Hawkins, and N. Desai Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143
94. G. Storm, and M.C. Woodle Polymers for drug delivery: the debate continues Drug Discov. Today 8 2003 62
95. J. Szebeni The interaction of liposomes with the complement system Crit. Rev. Ther. Drug Carrier Syst. 15 1998 57 88
96. J. Szebeni Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents Crit. Rev. Ther. Drug Carrier Syst. 18 2001 567 606
97. J. Szebeni Complement activation-related pseudoallergy: Mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents J. Szebeni The Complement System: Novel Roles in Health and Disease 2004 Kluwer Boston 399 440
98. J. Szebeni Hypersensitivity reactions to radiocontrast media: the role of complement activation Curr. Allergy Asthma Rep. 4 2004 25 30
99. J. Szebeni, and C.R. Alving Complement-mediated acute effects of liposome-encapsulated hemoglobin Artif. Cells Blood Substit. Immobil. Biotechnol. 27 1999 23 41
100. J. Szebeni, N.M. Wassef, H. Spielberg, A.S. Rudolph, and C.R. Alving Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation Biochem. Biophys. Res. Comm. 205 1994 255 263
101. J. Szebeni, N.M. Wassef, A.S. Rudolph, and C.R. Alving Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies Biochim. Biophys. Acta 1285 1996 127 130
102. J. Szebeni, H. Spielberg, R.O. Cliff, N.M. Wassef, A.S. Rudolph, and C.R. Alving Complement activation and thromboxane A2 secretion in rats following administration of liposome-encapsulated hemoglobin: Inhibition by soluble complement receptor type 1 Artif. Cells Blood Substit. Immobil. Biotechnol. 25 1997 379 392
103. J. Szebeni, N.M. Wassef, K.R. Hartman, A.S. Rudolph, and C.R. Alving Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1 Transfusion 37 1997 150 159
104. J. Szebeni, F.M. Muggia, and C.R. Alving Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study J. Natl. Cancer Inst. 90 1998 300 306
105. J. Szebeni, J.L. Fontana, N.M. Wassef, P.D. Mongan, D.S. Morse, D.E. Dobbins, G.L. Stahl, R. Bünger, and C.R. Alving Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody Circulation 99 1999 2302 2309
106. J. Szebeni, B. Baranyi, S. Savay, M. Bodo, D.S. Morse, M. Basta, G.L. Stahl, R. Bunger, and C.R. Alving Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction Am. J. Physiol. 279 2000 H1319 H1328
107. ®) J. Liposome Res. 10 2000 347 361
108. J. Szebeni, C.R. Alving, S. Savay, Y. Barenholz, A. Priev, D. Danino, and Y. Talmon Formation of complement-activating particles in aqueous solutions of Taxol: Possible role in hypersensitivity reactions Int. Immunopharmacol. 1 2001 721 735
109. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J.M. Metselaar, G. Storm, A. Chanan-Khan, L. Liebes, F.M. Muggia, R. Cohen, Y. Barenholz, and C.R. Alving Role of complement activation in hypersensitivity reactions to Doxil and HYNIC-PEG liposomes: experimental and clinical studies J. Liposome Res. 12 2002 165 172
110. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, M. Bodo, R. Bunger, and C.R. Alving The Interaction of liposomes with the complement system: in vitro and in vivo sssays Methods Enzymol. 373 2003 136 154
111. Szebeni, J., Baranyi, B., Savay, S., Bodo, M., Milosevits, J., Alving, C.R., Bunger, R., 2005. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol., in press.
112. A.J. Ten Tije, W.J. Loos, J. Verweij, S.D. Baker, K. Dinh, W.D. Figg, and A. Sparreboom Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches Clin. Pharmacol. Ther. 74 2003 509 510
113. J.M. Terwogt, B. Nuijen, W.W. Huinink, and J.H. Beijnen Alternative formulations of paclitaxel Cancer Treat. Rev. 23 1997 87 95
114. L.A. Trissel Pharmaceutical properties of paclitaxel and their effects on preparation and administration Pharmacotherapy 17 1997 133S 139S
115. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, E. Libson, F.M. Muggia, and A. Gabizon Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
116. O. Vandenplas, P. Hantson, A. Dive, and P. Mahieu Fulminant pulmonary edema following intravenous administration of radiocontrast media Acta Clin. Belg. 45 1990 334 339
117. G.M. Vercellotti, D.E. Hammerschmidt, P.R. Craddock, and H.S. Jacob Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis Blood 59 1982 1299 1304
118. H. Vik, A. Froysa, A. Sonstevold, K. Toft, P.S. Stov, and T. Ege Complement activation and histamine release following administration of roentgen contrast media Acta Radiol. Suppl. 399 1995 83 89
119. L. Webster, M. Linsenmeyer, M. Millward, C. Morton, J. Bishop, and D. Woodcock Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype J. Natl. Cancer Inst. 85 1993 1685 1690
120. S. Westaby, P. Dawson, M.W. Turner, and R.B. Pridie Angiography and complement activation. Evidence for generation of C3a anaphylatoxin by intravascular contrast agents Cardiovasc. Res. 19 1985 85 88
121. M. Westhoff-Bleck, J.S. Bleck, and S. Jost The adverse effects of angiographic radiocontrast media J. Allergy Clin. Immunol. 86 1990 684 686
122. G.C. Winkler Pulmonary intravascular macrophages in domestic animal species: review of structural and functional properties Am. J. Anat. 181 1988 217 234